A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-07-02.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.
Among the 42 studies testing adalimumab in Crohn Disease, this one is the 24th largest by enrollment, is one of 2 that started in 2008, is one of 22 in phase 3, and was the 13th registered.
1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 6–17
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
Maastricht University Medical Center · Sites in Netherlands
Ages 18–70
University Medical Center Groningen · Sites in Belgium, Netherlands, Spain
Ages 12–25
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 24 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 67 across 1,262 interventional studies indexed under Crohn Disease.
Median enrollment 143 across the 42 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 42 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
55 studies in Crohn Disease by AbbVie: 6 open now, 14 under way, 6 of them phase 3. Of 38 finished, 28 (74%) have results posted.
Among the 55 studies in Crohn Disease by AbbVie, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is the only one that started in 2008, is one of 16 in phase 3, and was the 2nd registered.
AbbVie’s Crohn Disease studies by the year they started, since 2007.
1 of the studies testing adalimumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06180382Centre Hospitalier Universitaire de Saint EtienneComparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration. | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 42 studies testing adalimumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 55 in Crohn Disease:
This tab as a report to print or save as PDF → With an account.
This was a multicenter, open-label study to evaluate the human monoclonal anti-TNF-α antibody adalimumab as an effective therapy for maintaining clinical response in pediatric participants with Crohn's disease (CD) and to gather long-term safety and tolerability data in this population. Participants were allowed to enroll in the study if they participated in and successfully completed Study M06-806 (NCT00409682) through Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, participants who were sexually active and of were to be practicing an approved method of throughout the study and for 150 days after study drug administration. Examples of approved methods of birth control included the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adalimumab was administered via subcutaneous injection. Dosage was based on body weight and clinical status, and ranged from 10, 20, or 40 mg every other week to 20 or 40 mg every week.
Biological: Adalimumab
Participants who enrolled into the study from blinded therapy in Study M06-806 received open-label (OL) therapy at a dose dependent on their body weight. Participants weighing ≥ 40 kg received 40 mg of adalimumab every other week (eow), and those who weighed \< 40 kg received 20 mg of adalimumab eow. Starting at Week 8, participants who had a disease flare may have been switched to every week (ew) treatment at the same dose of adalimumab received while on eow treatment. Participants who enrolled from OL therapy in Study M06-806 continued to receive the same dose they were receiving (i.e., 40 mg ew or 20 mg ew) at the Week 52 visit of Study M06-806. Adalimumab dose could have been decreased to the next lower treatment level for those with body weight changes. Participants who responded to treatment may have also had their dosage frequency decreased from ew to eow dosing, as well as a decrease in dosage.
Also known as: ABT-D2E7, Humira
Number of Participants Who Achieved Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission Over Time
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Number of Participants With Clinical Response as Defined by Pediatric Crohn's Disease Activity Index (PCDAI) Score Over Time
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline PCDAI value was defined as the last non-missing value on or before the date of the first dose of study drug during Study M06-806. Clinical response was defined as a PCDAI ≥ 15 points lower than the Study M06-806 baseline PCDAI value.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Remission Over Time
The CDAI includes 8 variables encompassing both subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept track of daily symptoms on a diary card, and the daily symptom scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and \> 450 to define severely active disease. A CDAI was calculated at each visit for participants who were age 13 or older at Study M06-806 entry. The Study M06-806 Week 52 visit served as the baseline visit for this study.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Number of Participants Who Were in Crohn's Disease Activity Index (CDAI) Clinical Response Over Time
The CDAI includes 8 variables: subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight). Participants kept track of symptoms on a diary card, and scores were summed for the week. Each item is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. Scale: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for participants ≥ 13 yrs old at M06-806 entry. Clinical response was defined as a decrease from M06-806 Baseline CDAI value of ≥ 70 pts. The M06-806 Baseline value was defined as the last non-missing value on or before the date of the 1st dose of study drug in M06-806.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384, 408
Number of Participants in Steroid-free Pediatric Crohn's Disease Activity Index (PCDAI) Remission Over Time
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Number of Participants in Steroid-free Crohn's Disease Activity Index (CDAI) Remission Over Time
The CDAI includes 8 variables encompassing subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for subjects ≥ 13 years old at M06-806 entry. CDAI corticosteroid-free remission was defined as discontinued use at least 90 consecutive days prior to the respective visit and a CDAI \< 150 at that visit.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Mean Change From Baseline in Pediatric Crohn's Disease Activity Index (PCDAI) Over Time
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
Mean Change From Baseline in Crohn's Disease Activity Index (CDAI) Over Time
The CDAI includes 8 variables: participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease) and \> 450 (severely active disease). A CDAI was calculated at each visit for those who were ≥ 13 years old at Study M06-806 entry. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.
Time frame: Week 0, 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, 168, 192, 216, 240, 264, 288, 312, 336, 360, 384
| Milestone | Any Adalimumab |
|---|---|
| Started | 100 |
| Completed | 39 |
| Not completed | 61 |
| Withdrew: Lack of efficacy | 10 |
| Withdrew: Adverse event | 8 |
| Withdrew: Withdrew consent | 5 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Missing reason | 33 |
| Withdrew: Other, not specified | 4 |
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 67 |
| Week 4 | 65 |
| Week 8 | 67 |
| Week 12 | 60 |
| Week 24 | 59 |
| Week 36 | 60 |
| Week 48 | 54 |
| Week 60 | 60 |
| Week 72 | 49 |
| Week 84 | 54 |
| Week 96 | 54 |
| Week 108 | 54 |
| Week 120 | 52 |
| Week 144 | 51 |
| Week 168 | 44 |
| Week 192 | 44 |
| Week 216 | 36 |
| Week 240 | 37 |
| Week 264 | 31 |
| Week 288 | 24 |
| Week 312 | 14 |
| Week 336 | 8 |
| Week 360 | 7 |
| Week 384 | 2 |
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline PCDAI value was defined as the last non-missing value on or before the date of the first dose of study drug during Study M06-806. Clinical response was defined as a PCDAI ≥ 15 points lower than the Study M06-806 baseline PCDAI value.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 95 |
| Week 4 | 90 |
| Week 8 | 92 |
| Week 12 | 87 |
| Week 24 | 88 |
| Week 36 | 82 |
| Week 48 | 74 |
| Week 60 | 76 |
| Week 72 | 72 |
| Week 84 | 69 |
| Week 96 | 72 |
| Week 108 | 70 |
| Week 120 | 65 |
| Week 144 | 64 |
| Week 168 | 53 |
| Week 192 | 52 |
| Week 216 | 46 |
| Week 240 | 43 |
| Week 264 | 35 |
| Week 288 | 28 |
| Week 312 | 15 |
| Week 336 | 10 |
| Week 360 | 8 |
| Week 384 | 2 |
The CDAI includes 8 variables encompassing both subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. For symptoms scores, participants kept track of daily symptoms on a diary card, and the daily symptom scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 to indicate remission, 150 - 219 to define mildly active disease, 220 - 450 to define moderately active disease, and \> 450 to define severely active disease. A CDAI was calculated at each visit for participants who were age 13 or older at Study M06-806 entry. The Study M06-806 Week 52 visit served as the baseline visit for this study.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 58 |
| Week 4 | 55 |
| Week 8 | 58 |
| Week 12 | 53 |
| Week 24 | 54 |
| Week 36 | 52 |
| Week 48 | 48 |
| Week 60 | 49 |
| Week 72 | 47 |
| Week 84 | 46 |
| Week 96 | 45 |
| Week 108 | 45 |
| Week 120 | 42 |
| Week 144 | 40 |
| Week 168 | 35 |
| Week 192 | 31 |
| Week 216 | 27 |
| Week 240 | 26 |
| Week 264 | 23 |
| Week 288 | 17 |
| Week 312 | 15 |
| Week 336 | 8 |
| Week 360 | 7 |
| Week 384 | 1 |
The CDAI includes 8 variables: subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight). Participants kept track of symptoms on a diary card, and scores were summed for the week. Each item is assigned a specific weight, and the weighted values of the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. Scale: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for participants ≥ 13 yrs old at M06-806 entry. Clinical response was defined as a decrease from M06-806 Baseline CDAI value of ≥ 70 pts. The M06-806 Baseline value was defined as the last non-missing value on or before the date of the 1st dose of study drug in M06-806.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 55 |
| Week 4 | 56 |
| Week 8 | 56 |
| Week 12 | 51 |
| Week 24 | 52 |
| Week 36 | 53 |
| Week 48 | 48 |
| Week 60 | 48 |
| Week 72 | 45 |
| Week 84 | 47 |
| Week 96 | 45 |
| Week 108 | 47 |
| Week 120 | 40 |
| Week 144 | 41 |
| Week 168 | 34 |
| Week 192 | 33 |
| Week 216 | 28 |
| Week 240 | 28 |
| Week 264 | 24 |
| Week 288 | 18 |
| Week 312 | 15 |
| Week 336 | 9 |
| Week 360 | 7 |
| Week 384 | 1 |
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 23 |
| Week 4 | 23 |
| Week 8 | 23 |
| Week 12 | 20 |
| Week 24 | 21 |
| Week 36 | 19 |
| Week 48 | 19 |
| Week 60 | 24 |
| Week 72 | 17 |
| Week 84 | 19 |
| Week 96 | 20 |
| Week 108 | 18 |
| Week 120 | 19 |
| Week 144 | 17 |
| Week 168 | 16 |
| Week 192 | 15 |
| Week 216 | 13 |
| Week 240 | 13 |
| Week 264 | 11 |
| Week 288 | 9 |
| Week 312 | 5 |
| Week 336 | 2 |
| Week 360 | 1 |
The CDAI includes 8 variables encompassing subject-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease), and \> 450 (severely active disease). A CDAI was calculated at each visit for subjects ≥ 13 years old at M06-806 entry. CDAI corticosteroid-free remission was defined as discontinued use at least 90 consecutive days prior to the respective visit and a CDAI \< 150 at that visit.
| Participants | Any Adalimumab |
|---|---|
| Week 0 | 21 |
| Week 4 | 22 |
| Week 8 | 22 |
| Week 12 | 20 |
| Week 24 | 21 |
| Week 36 | 22 |
| Week 48 | 22 |
| Week 60 | 21 |
| Week 72 | 19 |
| Week 84 | 20 |
| Week 96 | 20 |
| Week 108 | 18 |
| Week 120 | 16 |
| Week 144 | 15 |
| Week 168 | 13 |
| Week 192 | 11 |
| Week 216 | 10 |
| Week 240 | 10 |
| Week 264 | 8 |
| Week 288 | 6 |
| Week 312 | 4 |
| Week 336 | 2 |
| Week 360 | 1 |
Pediatric Crohn's Disease Activity Index (PCDAI) is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.
| units on a scale | Any Adalimumab |
|---|---|
| Week 0 | -29.95 ± 11.459 |
| Week 4 | -30.15 ± 11.514 |
| Week 8 | -30.7 ± 11.415 |
| Week 12 | -29.19 ± 11.405 |
| Week 24 | -29.84 ± 11.702 |
| Week 36 | -30.89 ± 12.354 |
| Week 48 | -30.73 ± 11.983 |
| Week 60 | -32.78 ± 10.927 |
| Week 72 | -31.15 ± 10.404 |
| Week 84 | -32.94 ± 10.809 |
| Week 96 | -31.14 ± 11.33 |
| Week 108 | -33.54 ± 9.538 |
| Week 120 | -33.36 ± 10.441 |
| Week 144 | -34.38 ± 9.204 |
| Week 168 | -32.57 ± 11.273 |
| Week 192 | -33.00 ± 13.258 |
| Week 216 | -31.95 ± 12.344 |
| Week 240 | -34.18 ± 13.386 |
| Week 264 | -35.00 ± 9.242 |
| Week 288 | -35.95 ± 11.941 |
| Week 312 | -33.19 ± 14.318 |
| Week 336 | -35.23 ± 12.013 |
| Week 360 | -38.75 ± 10.69 |
| Week 384 | -46.25 ± 22.981 |
The CDAI includes 8 variables: participant-reported (symptoms, general well-being) and objective (medication usage, laboratory variables, presence of abdominal mass or complications, and weight) variables. Participants kept track of daily symptoms on a diary card, and the scores were summed for the week. Each item in the CDAI is assigned a specific weight, and the items are totaled to produce the CDAI score. Higher CDAI scores indicate greater disease activity; 0 is the lower limit with no set upper limit. The scale for the score is as follows: \< 150 (remission), 150 - 219 (mildly active disease), 220 - 450 (moderately active disease) and \> 450 (severely active disease). A CDAI was calculated at each visit for those who were ≥ 13 years old at Study M06-806 entry. The baseline value was defined as the last non-missing value on or before the date of the first dose of study drug in Study M06-806. Negative changes indicate reductions (improvement) in disease activity.
| units on a scale | Any Adalimumab |
|---|---|
| Week 0 | -160.8 ± 82.543 |
| Week 4 | -159.9 ± 79.986 |
| Week 8 | -164.45 ± 79.272 |
| Week 12 | -151.34 ± 87.157 |
| Week 24 | -161.51 ± 84.663 |
| Week 36 | -173.55 ± 77.358 |
| Week 48 | -162.08 ± 86.292 |
| Week 60 | -168.27 ± 82.605 |
| Week 72 | -165.4 ± 80.038 |
| Week 84 | -172.68 ± 86.223 |
| Week 96 | -168.3 ± 79.658 |
| Week 108 | -171.63 ± 85.19 |
| Week 120 | -179.14 ± 86.93 |
| Week 144 | -181.53 ± 78.99 |
| Week 168 | -175.05 ± 80.965 |
| Week 192 | -172.42 ± 76.381 |
| Week 216 | -173.13 ± 78.588 |
| Week 240 | -184.46 ± 94.114 |
| Week 264 | -186.42 ± 75.396 |
| Week 288 | -197.11 ± 88.029 |
| Week 312 | -199.00 ± 77.184 |
| Week 336 | -240.33 ± 97.395 |
| Week 360 | -224.86 ± 89.025 |
| Week 384 | -458.00 |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from the time of study drug administration in Study M06-806 until 70 days after the last dose of study drug in Study M06-807 (up to 470 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any Adalimumab | 0/100 (0%) | 48/100 (48%) | 98/100 (98%) |
| Event | Any Adalimumab |
|---|---|
| CROHN'S DISEASEGastrointestinal disorders | 25/100 |
| ANAL ABSCESSInfections and infestations | 3/100 |
| ANAEMIABlood and lymphatic system disorders | 2/100 |
| GASTRITISGastrointestinal disorders | 2/100 |
| GASTROENTERITISInfections and infestations | 2/100 |
| PNEUMONIAInfections and infestations | 2/100 |
| SUBCUTANEOUS ABSCESSInfections and infestations | 2/100 |
| LYMPHADENITISBlood and lymphatic system disorders | 1/100 |
| VERTIGOEar and labyrinth disorders | 1/100 |
| ABDOMINAL PAINGastrointestinal disorders | 1/100 |
| Event | Any Adalimumab |
|---|---|
| VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 39/100 |
| HEADACHENervous system disorders | 37/100 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 31/100 |
| OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders | 27/100 |
| DIARRHOEAGastrointestinal disorders | 26/100 |
| ABDOMINAL PAINGastrointestinal disorders | 24/100 |
| CROHN'S DISEASEGastrointestinal disorders | 24/100 |
| VOMITINGGastrointestinal disorders | 22/100 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 21/100 |
| PYREXIAGeneral disorders | 20/100 |
ITT Population: all participants who received ≥ 1 dose of adalimumab in Study M06-807 and also had ≥ 1 non-missing efficacy measurement during the study.
| Age, Continuous(years) | Any Adalimumab |
|---|---|
| Mean | 13.5 ± 2.5 |
| Sex: Female, Male(Participants) | Any Adalimumab |
|---|---|
| Female | 48 |
| Male | 52 |
| Race/Ethnicity, Customized(Participants) | Any Adalimumab |
|---|---|
| White | 93 |
| Black | 3 |
| Other | 2 |
| Multi-race | 2 |
| Body weight at Study M06-806 Baseline(Participants) | Any Adalimumab |
|---|---|
| < 40 kg | 38 |
| ≥ 40 kg | 62 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
The record gives a start of May 2008, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2018, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
AbbVie (prior sponsor, Abbott) →